Oxford, UK - 5 February 2025: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the ...

Overall, the adenoviral vector platform continues to evolve ... to enhance the safety and efficacy of adenoviral vectors in gene therapy and vaccine applications[5]. Adenoviral Vectors: Modified ...

ReiThera is proud to announce a new partnership with SillaJen through a comprehensive Master Service Agreement (MSA), which establishes ReiThera as the manufacturing partner for SillaJen’s innovative ...

Adenoviruses (Ad) are currently the most commonly used vectors in gene therapy clinical ... efficacy of the vector and causes toxic side effects. The 46 kDa coxsackie and adenovirus receptor ...

Exposing Adenoviruses: Inder Verma and colleagues used nude mice to study immune system and humoral responses during gene therapy ... immune responses to adenoviral vectors containing factor IX gene: ...

Ferring Pharma’s Adstiladrin is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy was evaluated in a multi-centre clinical study of ...

For recurrent respiratory papillomatosis (RRP), novel gene therapy to jump-start immunity to the human papillomavirus (HPV) ...

Intraperitoneal delivery of adenoviral gene therapy in vivo is safe and nontoxic. The use of new diluents, already used in peritoneal renal dialysis, will improve drug delivery, reduce therapeutic ...

The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the ...